This implies a strong and bidirectional correlation between MAFLD and T2DM, thus requiring a therapy plan that simultaneously targets both T2DM (e.g., by using pioglitazone or GLP1-RA) and risk factors for MAFLD. This evidence concerns the gene GCG and type 2 diabetes mellitus.